EryDel is a company focused on developing and commercializing of innovative therapies and diagnostic tools based on the use of autologous red blood cells as agent carriers, selective drug targeting system, agent passive reservoirs and circulating bioreactors. The company owns a proprietary technology that allow to encapsulate any kind of active agents within a small quantity of autologous blood with automatic, reliable and a reproducible system.